Xaliproden
- Generic Name
- Xaliproden
- Drug Type
- Small Molecule
- Chemical Formula
- C24H22F3N
- CAS Number
- 135354-02-8
- Unique Ingredient Identifier
- V8QL94KNQO
- Indication
Investigated for use/treatment in amyotrophic lateral sclerosis (ALS) and alzheimer's disease.
Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2016-05-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 102
- Registration Number
- NCT00603577
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.
Phase 3
Completed
- Conditions
- MetastasesColorectal NeoplasmsColorectal Carcinoma
- Interventions
- First Posted Date
- 2006-03-21
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 879
- Registration Number
- NCT00305188
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy
Phase 3
Completed
- Conditions
- MetastasesColorectal NeoplasmsColorectal Carcinoma
- First Posted Date
- 2006-01-04
- Last Posted Date
- 2006-09-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 620
- Registration Number
- NCT00272051
Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
Phase 3
Completed
- Conditions
- Alzheimer Disease
- First Posted Date
- 2005-02-21
- Last Posted Date
- 2008-08-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1455
- Registration Number
- NCT00104013
- Locations
- 🇺🇸
Neurological Center, Fort Wayne, Indiana, United States
🇺🇸Synergy Medical, Saginaw, Michigan, United States
🇺🇸CNS Healthcare, Jacksonville, Florida, United States
18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
Phase 3
Completed
- Conditions
- Alzheimer Disease
- First Posted Date
- 2005-02-14
- Last Posted Date
- 2008-08-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1306
- Registration Number
- NCT00103649
- Locations
- 🇺🇸
Neurology Clinical Research, Inc., Plantation, Florida, United States
🇺🇸Clinical Trials Research Services, Pittsburgh, Pennsylvania, United States
🇺🇸Margolin Brain Institute, Fresno, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath